When must manufacturers address pricing errors related to the 340B program?

Manufacturers must address pricing errors related to the 340B program within five days. This time frame is crucial because timely corrections ensure that covered entities receive the correct prices for the drugs they purchase under the 340B program. The requirement emphasizes the importance of accountability and responsiveness from manufacturers to maintain the integrity of the pricing system. Additionally, addressing issues quickly helps to prevent long-term impacts on covered entities’ operations and finances, supporting the program's overall goal of making medications more affordable for vulnerable populations. The urgency reflected in this brief response time aligns with the program’s objectives of facilitating access to necessary medications in a timely manner.